AR064009A1 - Metodo de inmunizacion contra los 4 serotipos del dengue - Google Patents
Metodo de inmunizacion contra los 4 serotipos del dengueInfo
- Publication number
- AR064009A1 AR064009A1 ARP070105280A ARP070105280A AR064009A1 AR 064009 A1 AR064009 A1 AR 064009A1 AR P070105280 A ARP070105280 A AR P070105280A AR P070105280 A ARP070105280 A AR P070105280A AR 064009 A1 AR064009 A1 AR 064009A1
- Authority
- AR
- Argentina
- Prior art keywords
- dengue
- administration
- serotips
- immunization method
- method against
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title abstract 4
- 206010012310 Dengue fever Diseases 0.000 title abstract 4
- 208000025729 dengue disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940031346 monovalent vaccine Drugs 0.000 abstract 1
- 229940031351 tetravalent vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Método para inducir proteccion contra los 4 serotipos del dengue en un paciente, que comprende: (a) la administracion de una vacuna monovalente comprende un virus vacunal de un primer serotipo del dengue, y (b) la administracion de una vacuna tetravalente que comprende virus vacunales de los cuatro serotipos del dengue, en el cual la administracion (b) se realiza entre por lo menos 30 días y no más de 12 meses después de la primera administracion (a).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0655255A FR2909286B1 (fr) | 2006-12-01 | 2006-12-01 | Methode d'immunisation contre les 4 serotypes de la dengue |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064009A1 true AR064009A1 (es) | 2009-03-04 |
Family
ID=38198298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105280A AR064009A1 (es) | 2006-12-01 | 2007-11-28 | Metodo de inmunizacion contra los 4 serotipos del dengue |
Country Status (16)
Country | Link |
---|---|
US (2) | US7718359B2 (es) |
EP (1) | EP2099483B1 (es) |
JP (1) | JP5269803B2 (es) |
KR (1) | KR20090087890A (es) |
CN (1) | CN101541344A (es) |
AR (1) | AR064009A1 (es) |
AU (1) | AU2007327367B2 (es) |
BR (1) | BRPI0718927A2 (es) |
CA (1) | CA2668570A1 (es) |
FR (1) | FR2909286B1 (es) |
IL (2) | IL198466A (es) |
MX (1) | MX2009004223A (es) |
MY (1) | MY180698A (es) |
TW (1) | TWI400249B (es) |
WO (1) | WO2008065315A1 (es) |
ZA (1) | ZA200902540B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5227172B2 (ja) * | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
CA2716399C (en) | 2008-03-05 | 2020-07-21 | Pierre Chouvenc | Process for stabilizing an adjuvant containing vaccine composition |
EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
SG176299A1 (en) * | 2009-06-01 | 2012-01-30 | Inviragen Inc | Compositions and methods for administration of vaccines against dengue virus |
CA2770888C (en) * | 2009-08-31 | 2020-04-14 | Gen-Probe Incorporated | Dengue virus assay |
EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
US8920813B2 (en) | 2010-12-20 | 2014-12-30 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
US20150196631A1 (en) | 2012-07-24 | 2015-07-16 | Sanofi Pasteur | Vaccine compositions |
AU2013295016A1 (en) | 2012-07-24 | 2015-01-29 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
US9861692B2 (en) * | 2013-06-21 | 2018-01-09 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
CN106999564A (zh) | 2014-09-02 | 2017-08-01 | 赛诺菲巴斯德有限公司 | 针对登革热病毒疾病的疫苗组合物 |
BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
US10004795B2 (en) * | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
US11690903B2 (en) | 2017-10-05 | 2023-07-04 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
JP2021536463A (ja) | 2018-09-05 | 2021-12-27 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | デング熱ワクチン単位用量及びその投与 |
MX2022001742A (es) | 2019-08-16 | 2022-04-07 | Takeda Vaccines Inc | Metodos para prevenir el dengue y la hepatitis a. |
EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
EP4375381A1 (en) | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4224499A (en) | 1998-05-29 | 1999-12-13 | Epimmune, Inc. | Identification of broadly reactive dr restricted epitopes |
DE60041250D1 (de) * | 1999-03-26 | 2009-02-12 | Us Army | Multivalenter dengue-virus impfstoff |
US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
AU2001238441B2 (en) * | 2000-02-16 | 2006-10-26 | Mahidol University | Avirulent, immunogenic flavivirus chimeras |
EP1159969A1 (fr) | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
EP1159968B1 (fr) * | 2000-05-30 | 2008-10-29 | Mahidol University | Souches atténuées du virus de la Dengue et leur utilisation dans une composition vaccinale |
US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
CN1791433B (zh) * | 2003-03-24 | 2010-05-26 | 斯克里普斯研究学院 | 抗肿瘤生长的dna疫苗及其使用方法 |
WO2006134433A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
CN101238209B (zh) * | 2005-06-17 | 2013-02-13 | 赛诺菲巴斯德有限公司 | 登革血清型2减毒株 |
JP5227172B2 (ja) * | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
AR061197A1 (es) * | 2006-06-07 | 2008-08-13 | Sanofi Pasteur | Cepas del virus 3 del dengue vivas atenuadas |
FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
-
2006
- 2006-12-01 FR FR0655255A patent/FR2909286B1/fr not_active Expired - Fee Related
-
2007
- 2007-11-14 TW TW096143113A patent/TWI400249B/zh not_active IP Right Cessation
- 2007-11-21 US US11/944,311 patent/US7718359B2/en not_active Expired - Fee Related
- 2007-11-28 AR ARP070105280A patent/AR064009A1/es unknown
- 2007-11-30 BR BRPI0718927-3A2A patent/BRPI0718927A2/pt not_active IP Right Cessation
- 2007-11-30 WO PCT/FR2007/052431 patent/WO2008065315A1/fr active Application Filing
- 2007-11-30 AU AU2007327367A patent/AU2007327367B2/en not_active Ceased
- 2007-11-30 CN CNA2007800439553A patent/CN101541344A/zh active Pending
- 2007-11-30 KR KR1020097010676A patent/KR20090087890A/ko active IP Right Grant
- 2007-11-30 EP EP07866551.0A patent/EP2099483B1/fr not_active Not-in-force
- 2007-11-30 JP JP2009538758A patent/JP5269803B2/ja not_active Expired - Fee Related
- 2007-11-30 ZA ZA200902540A patent/ZA200902540B/xx unknown
- 2007-11-30 MY MYPI20091957A patent/MY180698A/en unknown
- 2007-11-30 CA CA002668570A patent/CA2668570A1/en not_active Abandoned
- 2007-11-30 MX MX2009004223A patent/MX2009004223A/es active IP Right Grant
-
2009
- 2009-04-30 IL IL198466A patent/IL198466A/en not_active IP Right Cessation
-
2010
- 2010-03-05 US US12/718,931 patent/US20100239612A1/en not_active Abandoned
-
2013
- 2013-12-19 IL IL230052A patent/IL230052A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI400249B (zh) | 2013-07-01 |
AU2007327367B2 (en) | 2013-05-09 |
IL198466A0 (en) | 2011-08-01 |
US7718359B2 (en) | 2010-05-18 |
MX2009004223A (es) | 2009-04-30 |
AU2007327367A1 (en) | 2008-06-05 |
BRPI0718927A2 (pt) | 2014-04-08 |
US20080131460A1 (en) | 2008-06-05 |
US20100239612A1 (en) | 2010-09-23 |
WO2008065315A1 (fr) | 2008-06-05 |
MY180698A (en) | 2020-12-07 |
FR2909286B1 (fr) | 2012-06-08 |
EP2099483B1 (fr) | 2013-12-25 |
TW200829599A (en) | 2008-07-16 |
KR20090087890A (ko) | 2009-08-18 |
EP2099483A1 (fr) | 2009-09-16 |
IL198466A (en) | 2014-01-30 |
FR2909286A1 (fr) | 2008-06-06 |
JP5269803B2 (ja) | 2013-08-21 |
IL230052A0 (en) | 2014-01-30 |
CN101541344A (zh) | 2009-09-23 |
CA2668570A1 (en) | 2008-06-05 |
ZA200902540B (en) | 2010-07-28 |
JP2010511022A (ja) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
ECSP10010723A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso | |
AR061887A1 (es) | Una composicion de vacuna contra el dengue | |
AR063057A1 (es) | Metodo de inmunizacion contra los 4 serotipos de dengue | |
CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
CO6160334A2 (es) | Metodo para la elaboracion de una vacuna de conbinacion para proteger contra polio | |
CO6190623A2 (es) | Vacuna salmonella | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
CR11122A (es) | Vacuna de influenza de emulsion de aceite en agua | |
PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
CR8638A (es) | Vacuna agalactiae estreptococos | |
PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
WO2007006712A3 (en) | Mycoplasma subunit vaccine | |
CL2011003043A1 (es) | Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue. | |
CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
CO6290701A2 (es) | Vacuna de vih que comprende una proteina de fusion y un agente estabilizador | |
AR056712A1 (es) | Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus | |
AR051636A1 (es) | Vacunas multivalentes para la gripe aviar | |
CO6361950A2 (es) | Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1 | |
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
CL2009000287A1 (es) | Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav. | |
AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias | |
CO2022007006A2 (es) | Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar | |
AR056753A1 (es) | Vacuna de primera dosis -refuerzo para la proteccion de equinos contra la influenza equina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |